Implementing MES is not a decision that can be taken lightly. Every aspect of the manufacturing process is impacted by an MES implementation and maintenance is critical. Too many companies get their MES over the line, but fail to push on and extract the real value from the system. Best practices would suggest that applying a comprehensive support level can expedite your return on investment.
MES has reached maturity in the pharmaceutical industry; learn how to reap the rewards.
The first part of the webinar will present the findings of a study that demonstrates MES is being adopted by the pharmaceutical industry. The second part will explain how to maintain and maximise your investment in MES.
Mike James,
Chairman of MOM Institute
Mike has spent his whole career in manufacturing and he specializes in sustainable solutions for the manufacturing industry. Mike is a member of the MES Governance Boards at Rolls-Royce Aerospace and regularly provides MES/MOM workshops to pharmaceutical companies whilst also leading a number of initiatives in the Automotive and Food industries.
Desmond Savage,
MOM/MES Consultant
Desmond works as MOM/MES consultant for ATS and has hands on experience working in the Life Science industry as an MES manufacturing engineer and validation specialist. Desmond recently published an article in ISPE's Pharmaceutical Engineering on the topic of MES for the Pharmaceutical Industry. Desmond is the chairperson for MESA Ireland and is qualified with a Masters in Advanced Manufacturing Technology from the University of Limerick, Ireland.
- Manufacturing Execution Systems (MES) technologies are ready for the pharmaceutical industry
- Understand that MES is a mature technology and represents a low risk of failure
- The importance of putting a maintenance process in place for MES
- How support level agreements help the end user concentrate on their core business
- Systems Analysts
- Project Managers/Owners
- Quality
- Production
- IT
- Operations
- Automation
